Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $26.90, moving +1.01% from the previous trading session.
Hims & Hers: Ready For Liftoff In 2025
Despite a recent 30% stock drawdown, Hims & Hers Health, Inc. remains a “Strong Buy” due to its undervaluation and long-term growth potential in the healthcare tech market. Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its strong growth trajectory. Management's raised FY-2024 revenue outlook and strategic initiatives, including new weight loss offerings and personalization, bolster confidence in sustained growth.
Is Hims & Hers Health a Millionaire Maker?
Hot telehealth stock Hims & Hers Health (HIMS -3.93%) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high.
3 Hot Stocks That Can Double Again in 2025
Some of the hottest stocks of 2024 may surprise you. A few more than 100 stocks with market caps north of $2 billion doubled over the past year.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Still Trading At A Massive Discount
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation. HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase. The company is expanding its product offerings and leveraging AI through MedMatch, enhancing treatment consistency and customer satisfaction, further solidifying its market position.
Will the falling Hims & Hers stock price recover in 2025?
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Health and Walgreens Boots Alliance and CVS Health, plunged.
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this video.
Hims and Hers Health Stock Testing Key Trendline
Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15.
CEO of HIMS dumps over $6 million of stock
Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven't exactly been performing well as of late.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
